2022-10-10T16:19:54-05:00 2021-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2021-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQ 5714831700 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 LINDA A JENSEN EVP & CFO 5714831700 2022-10-07 1 LINDA JENSEN 999009999 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2022-10-05 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z CONQUER CANCER & CONQUER CANCER FDTN NANCY DALY MS MPH 2318 MILL RD STE 800 ALEXANDRIA VA 22314 26396758 0 X WWW.CONQUER.ORG X 1999 VA TO ACCELERATE BREAKTHROUGHS IN LIFESAVING RESEARCH AND EMPOWER PEOPLE EVERYWHERE TO CONQUER CANCER. 20 19 0 189 0 0 34795083 21747229 622500 312459 -2363054 2617495 -11891 -35881 33042638 24641302 14740700 19181199 0 0 0 0 222000 60000 5310959 10278908 9164357 25241608 28405556 7801030 -3764254 107923414 109850269 9249329 10347798 98674085 99502471 X CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY. 0 0 15907019 14002989 312459 RESEARCH: THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER HAS A DEMONSTRATED TRACK RECORD OF SUPPORTING THE EARLY CAREER DEVELOPMENT OF ONCOLOGY RESEARCHERS, INCLUDING IDENTIFYING AND NURTURING THOSE WHO HAVE BECOME NOTABLE LEADERS AND INNOVATORS IN THE FIELD. PAST GRANT RECIPIENTS HAVE BECOME HEADS OF LARGE CANCER INSTITUTIONS AND PRESIDENTS OF MAJOR ONCOLOGY SOCIETIES, AS WELL AS GUIDED THE NATIONAL ONCOLOGY CONVERSATION THROUGH SERVICE ON BOARDS AND COMMITTEES. ADDITIONALLY, PAST RECIPIENTS HAVE ALSO INVESTED IN THE NEXT GENERATION OF YOUNG INVESTIGATORS BY SERVING AS MENTORS TO NEWLY CHOSEN CONQUER CANCER GRANTEES. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $146 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,400 RECIPIENTS IN 78 COUNTRIES. HIGHLIGHTS OF 2021 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $900,000 PROVIDED TWO (2) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS, INCLUDING CLINICAL RESEARCH STUDIES AND/OR TRANSLATIONAL RESEARCH INVOLVING HUMAN SUBJECTS. ONE AWARD WAS TO SUPPORT DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER AND THE SECOND ON IMMUNE CHECKPOINT INHIBITOR THERAPY. *CAREER DEVELOPMENT AWARD (CDA): $4,200,000 PROVIDED TWENTY-ONE (21) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,700,000 PROVIDED NINETY-FOUR (94) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $250,000 PROVIDED FIVE (5) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS CONDUCTING RESEARCH IN LOW RESOURCE SETTINGS ON SCIENTIFIC QUESTIONS SPECIFIC TO THOSE SETTINGS, WITH THE POTENTIAL TO OFFER "REVERSE INNOVATION" INSIGHTS TO INFLUENCE ONCOLOGY PRACTICE IN A WIDE RANGE OF RESOURCE SETTINGS, BY INVESTIGATORS IN HIGH RESOURCE SETTINGS ON ISSUES IN RESOURCE-LIMITED SETTINGS, OR COLLABORATIVE RESEARCH BETWEEN INVESTIGATORS IN BOTH HIGH AND LOW RESOURCE SETTINGS ON QUESTIONS OF SHARED CONCERN. THE GOAL FOR THE GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD IS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY, AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. *INTERNATIONAL INNOVATION GRANT: $260,000 PROVIDED THIRTEEN (13) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT CAN HAVE A SIGNIFICANT IMPACT ON CANCER CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES. THE INTERNATIONAL INNOVATION GRANT PROGRAM IS INTENDED TO SUPPORT PROPOSALS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. *GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP: $50,000 PROVIDED ONE (1) ONE-YEAR FELLOWSHIP THAT ENABLES AN EARLY-CAREER INVESTIGATOR TO UNDERTAKE A BREAST CANCER PROJECT UNDER THE MENTORSHIP OF THE GIANNI BONADONNA BREAST CANCER AWARD RECIPIENT.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER COLLABORATES WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER GRANTS PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE. CONQUER CANCER WORKS WITH ORGANIZATIONS TO DEVELOP GRANTS PROGRAMS THAT HAVE REAL IMPACT ON RESEARCHERS AND PATIENT CARE, INSTITUTE PEER REVIEW PROCESSES THAT ENSURE APPLICATIONS MEET THE HIGHEST STANDARDS, AND ESTABLISH PROCESSES THAT MAKE ADMINISTRATION OF RESEARCH GRANTS BOTH EFFECTIVE AND EFFICIENT. 4814004 4453739 PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S COMPREHENSIVE SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2021 INCLUDE THE FOLLOWING: *VIRTUAL ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY AND ATTRACTED APPROXIMATELY 32,950 PARTICIPANTS WORLDWIDE IN 2021. THE ANNUAL MEETING PROVIDES A FORUM TO EXPLORE CUTTING EDGE SCIENCE AND EDUCATION ACROSS MULTIPLE DISCIPLINES AND FIELDS IN ONCOLOGY WHILE ADDRESSING THE NEED FOR EVERY PATIENT TO RECEIVE THE HIGHEST QUALITY AND EQUITABLE CANCER CARE AVAILABLE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS.*GENITOURINARY CANCERS (GU) SYMPOSIUM: THIS IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. *QUALITY CARE SYMPOSIUM: THIS IS AN UNPARALLELED OPPORTUNITY TO LEVERAGE THE MOST UP-TO-DATE SCIENCE AND DISCOVER PROVEN STRATEGIES AND TOOLS CRITICAL TO MAKING KEY DECISIONS THAT CAN REDUCE DISPARITIES IN CARE FOR EVERY PATIENT, EVERY DAY, EVERYWHERE. THE SYMPOSIUM BRINGS TOGETHER LEADERS IN THE FIELD TO SHARE STRATEGIES AND METHODS FOR MEASURING AND IMPROVING THE QUALITY OF CANCER CARE AND DISSEMINATES INFORMATION ON THE IMPROVEMENT OF THE QUALITY OF PATIENT AND SURVIVOR CARE.*EDUCATION SCHOLARS PROGRAM (ESP): THIS PROGRAM IS A YEARLONG PROFESSIONAL DEVELOPMENT INITIATIVE, WHICH AIMS TO CREATE A COHORT OF ONCOLOGISTS WITH BOTH LEADERSHIP SKILLS AND EXPERTISE IN LEARNING SCIENCE AND EDUCATION DESIGN. THROUGH THIS PROGRAM, ESP PARTICIPANTS BECOME EXPERIENCED IN USING THE LATEST LEARNING SCIENCE TO MORE EFFECTIVELY PRESENT GROUND-BREAKING CANCER DEVELOPMENTS TO THE ONCOLOGY COMMUNITY TO ADVANCE CANCER RESEARCH AND IMPROVE PATIENT CARE. PARTICIPANTS IN THE EDUCATION SCHOLARS PROGRAM RECEIVE DIDACTIC AND HANDS-ON TRAINING BY LEARNING SCIENCE SCHOLARS ON HOW TO DESIGN EFFECTIVE EDUCATIONAL PROGRAMS FOR ADULT LEARNERS.*MERIT AWARDS: $226,000 PROVIDED TWO HUNDRED TWENTY-ONE (221) MERIT AWARDS WHICH PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. *MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR): $221,000 PROVIDED TWENTY-SIX (26) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER. A MENTORING COMPONENT IS INCLUDED IN THE MSR WHEREBY AWARD RECIPIENTS ARE PAIRED WITH A CLINICAL ONCOLOGIST WHO PROVIDES ACADEMIC AND CAREER GUIDANCE, BOTH DURING AND FOLLOWING THE ROTATION EXPERIENCE. *ANNUAL MEETING RESEARCH AWARD (AMRA): $10,500 PROVIDED FOR SEVEN (7) ANNUAL MEETING RESEARCH AWARDS FOR THOSE UNDERREPRESENTED IN MEDICINE (UIM). IN ADDITION TO ATTENDING THE VIRTUAL ASCO ANNUAL MEETING, RECIPIENTS OF THE AMRA PARTICIPATED IN THE 2021 VIRTUAL ABSTRACT FORUM TO PRESENT THEIR ONCOLOGY-RELATED RESEARCH AND RECEIVE FEEDBACK ON THEIR PRESENTATION SKILLS AND WERE ALSO MATCHED WITH AN ONCOLOGIST-IN-TRAINING WHO SERVED AS A MENTOR DURING THE VIRTUAL ASCO ANNUAL MEETING. ADDITIONALLY, RECIPIENTS WERE ALSO ABLE TO PARTICIPATE IN THE 2021-22 DIVERSITY MENTORING PROGRAM, A 6- TO 12-MONTH MENTORSHIP PROGRAM DESIGNED TO ENCOURAGE UIM MEDICAL STUDENTS AND RESIDENTS TO PURSUE REWARDING CAREERS IN ONCOLOGY. THE PROGRAM SEEKS TO EDUCATE PHYSICIANS-IN-TRAINING ABOUT ONCOLOGY CAREERS BY FOSTERING RELATIONSHIPS WITH MENTORS WHO CAN PROVIDE CAREER AND EDUCATIONAL GUIDANCE AND SERVE AS A PROFESSIONAL RESOURCE. ADDITIONALLY, AMRA RECIPIENTS WERE INVITED TO PARTICIPATE IN THE ASCO VIRTUAL PROFESSIONAL DEVELOPMENT SESSIONS AND THE VIRTUAL GRANT WRITING WORKSHOP. 569240 523801 QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED. THE QUALITY AND EQUITABLE ACCESS TO CARE PROGRAMS AND INITIATIVES SUPPORTED BY CONQUER CANCER IN 2021 INCLUDE THE FOLLOWING: *COVID-19 IMPACTS CANCER INITIATIVE : THE IMPACT OF COVID-19 ON CANCER CARE CONTINUED INTO 2021 AND CONQUER CANCER CONTINUED ITS WORK IN REPONDING TO THIS CRISIS THROUGH ITS SUPPORT OF THE FOLLOWING ACTIVITIES: -ASCO SURVEY ON COVID-19 IN ONCOLOGY REGISTRY (ASCO REGISTRY)- TO HELP THE ONCOLOGY COMMUNITY LEARN ABOUT THE PATTERN OF SYMPTOMS AND SEVERITY OF COVID-19 AMONG PATIENTS WITH CANCER AND HOW INFECTIONS IMPACT THE DELIVERY OF CANCER CARE AND PATIENT OUTCOMES, CONQUER CANCER'S AFFILIATE, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), PROVIDED THE MEANS FOR THE ONCOLOGY COMMUNITY TO SUBMIT DATA ABOUT CANCER PATIENTS WITH COVID-19. DATA WAS MADE AVAILABEL TO THE PUBLIC ON ASCO'S WEBSITE THROUGH A REGISTRY DATA DASHBOARD AND REGISTRY DATA MAP. GRANTS WERE ALSO ISSUED TO SUPPORT THE RAPID ANALYSIS OF REGISTRY DATA, MANUSCRIPT DEVELOPMENT, AND DISSEMINATION OF FINDINGS INTO HIGH-IMPACT SCIENTIFIC, PEER-REVIEWED MANUSCRIPTS SO THOSE WHO TREAT CANCER PATIENTS WERE ABLE TO RECIVE VITAL INFORMATION ON HOW THE PANDEMIC CONTINUES TO IMPACT PATIENTS WITH CANCER. -MEASURE DEVELOPMENT- UNDERSTANDING THE IMPACT COVID-19 HAD ON PEOPLE WITH CANCER REQUIRES ANALYSIS OF CARE DELIVERY AND OUTCOMES, WHICH REQUIRES QUALITY MEASURES. THIS WORK PROVIDED A BETTER UNDERSTANDING OF HOW THE PANDEMIC AFFECTED SAFETY, EQUITY AND TIMELINESS OF CANCER CARE TO GUIDE CHANGES FOR THE FUTURE TO ENSURE QUALITY CARE FOR ALL PEOPLE WITH CANCER.-EDUCATIONAL RESOURCES FOR PATIENTS WITH CANCER AND CANCER SURVIVORS - REGULARLY UPDATED INFORMATION IN ENGLISH AND SPANISH ABOUT COVID-19 WAS PROVIDED FOR PEOPLE WITH CANCER AND CANCER SURVIVORS THROUGH ASCO'S PATIENT INFORMATION WEBSITE, CANCER.NET. -EDUCATION FOR CANCER CARE PROVIDERS - REGULARLY UPDATED INFORMATION ON TREATMENT OF PATIENTS WITH COVID-19 WAS PROVIDED TO SUPPORT CLINICIANS, THE CANCER CARE DELIVERY TEAM, AND PATIENTS WITH CANCER. *EQUITY, DIVERSITY AND INCLUSION: ASSURING HIGH-QUALITY AND EQUITABLE CARE FOR EVERY PATIENT WITH CANCER HAS BEEN AT THE CORE OF THE THREE MISSION PILLARS (RESEARCH, EDUCATION, AND QUALITY) OF ASCO AND CONQUER CANCER. BOTH ORGANIZATIONS HAVE ALWAYS SOUGHT TO ADDRESS DISPARITIES AND INEQUITIES IN CARE EXPERIENCED BY MARGINALIZED POPULATIONS AND THE LACK OF DIVERSITY IN THE ONCOLOGY WORKFORCE. WHILE THE COMMITMENT TO ADDRESS THESE GAPS IN CARE IS LONGSTANDING, BOTH ASCO AND CONQUER CANCER HAVE SIGNIFICANTLY EXPANDED THEIR EQUITY, DIVERSITY, AND INCLUSION PROGRAMS TO ACHIEVE THREE OVERARCHING GOALS: -MAKE CLINICAL TRIALS MORE ACCURATELY REPRESENT THE POPULATION OF PATIENTS WITH CANCER AND ENSURE THAT THEY ARE ROUTINELY OFFERED AS A TREATMENT OPTION, WITH ALL PATIENTS HAVING EQUITABLE ACCESS. -MAKE THE ONCOLOGY WORKFORCE BETTER REFLECTS THE DIVERSITY OF THE POPULATION AND ENSURE THAT IT IS WELL-EQUIPPED TO DELIVER HIGH-QUALITY, EQUITABLE CARE FOR EVERY PATIENT. -DECREASE THE NUMBER OF BARRIERS TO ACCESSING CANCER CARE BY ENSURING THAT ONCOLOGY PRACTICES HAVE THE RESOURCES NEEDED TO ADVOCATE FOR PATIENTS AND TO SUSTAINABLY DELIVER HIGH-QUALITY, EQUITABLE CARE TO ALL PATIENTS.*QUALITY TRAINING PROGRAM: CONQUER CANCER SUPPORTS ASCO'S QUALITY TRAINING PROGRAM, WHICH EMPOWERS PRACTICE TEAMS TO IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE BY TEACHING TEAMS HOW TO BALANCE QUALITY IMPROVEMENT PROJECTS WITH DEMANDING SCHEDULES AND COMPETING PRIORITIES. WINTER AND SUMMER SESSIONS PROVIDED VIRTUAL CONTENT SPECIFICALLY FOR ONCOLOGY PRACTICE TEAMS AND INCLUDED ACCESS TO RENOWNED FACULTY AND COACHES DURING FIVE FOCUSED DAYS OF LEARNING. 215853 200670 PATIENT EDUCATION AND INFORMATION: CONQUER CANCER SUPPORTS PROGRAMS AND ACCURATE, DOCTOR-APPROVED CANCER INFORMATION AND RESOURCES BOTH IN PRINT AND ONLINE, THAT EDUCATE PATIENTS AND THE PUBLIC ABOUT CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. FUNDING IN THIS AREA ALLOWS CONQUER CANCER TO CONTINUE AND EXPAND ITS WORK TO INFORM PATIENTS. A HIGHLIGHT OF PATIENT EDUCATION AND INFORMATION PROGRAMS AND ACTIVITIES SUPPORTED BY CONQUER CANCER IN 2021 IS: *CANCER.NET- CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. THE WEBSITE PROVIDES TIMELY, COMPREHENSIVE INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. ALL CONTENT IS SUBJECT TO A FORMAL PEER-REVIEW PROCESS AND INCLUDES PEER-REVIEWED INFORMATION ON MORE THAN 120 TYPES OF CANCER AND SYNDROMES. INFORMATION IS DELIVERED IN WRITTEN ARTICLES, VIDEOS, AND AUDIO PODCASTS. THIS INFORMATION IS MADE AVAILABLE FREE TO THE PUBLIC. 215853 200670 21506116 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 230 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 20 19 1 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 0 0 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NC OR PA RI SC TN UT VA WV WI NY X X LINDA JENSEN EVP CFO 5714831300 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 CLIFFORD HUDIS MD FACP FASCO CHIEF EXECUTIVE OFFICER 6.50 31.00 X X 0 888725 21750 HOWARD BURRIS III MD FACP FASC CHAIR 2.00 X X 0 0 0 SANDRA SWAIN MD FACP FASCO SECRETARY 1.00 X X 0 0 0 ALEXANDER W CASDIN TREASURER 1.00 X X 0 0 0 KATHRYN BEAL MD BOARD MEMBER 1.00 X 0 0 0 RICHARD BOXER MD FACS BOARD MEMBER 1.00 X 0 0 0 RICCARDO BRAGLIA BOARD MEMBER 1.00 X 0 0 0 SUSAN L COHN MD FASCO BOARD MEMBER 1.00 X 0 0 0 LAWRENCE H EINHORN MD FASCO BOARD MEMBER 1.00 X 0 0 0 RAJ MANTENA RPH BOARD MEMBER 1.00 X 0 0 0 THOMAS A MARSLAND MD FASCO BOARD MEMBER 1.00 X 0 0 0 ROBERT J MAYER MD FASCO BOARD MEMBER 1.00 X 0 0 0 GERALD J MCDOUGALL BOARD MEMBER 1.00 X 0 0 0 ANNE MOORE MD FASCO BOARD MEMBER 1.00 X 0 0 0 W CHARLES PENLEY MD FASCO BOARD MEMBER 1.00 X 0 0 0 AMY C PETERSON MD BOARD MEMBER 1.00 X 0 0 0 THOMAS G ROBERTS JR MD FASCO BOARD MEMBER 1.00 X 0 0 0 STEVEN T ROSEN MD FACP FASCO BOARD MEMBER 1.00 X 0 0 0 MARGARET A TEMPERO MD FASCO BOARD MEMBER 1.00 X 0 0 0 DEANNA B VAN GESTEL BOARD MEMBER 1.00 X 0 0 0 LINDA JENSEN CPA CFO & EXECUTIVE VP 1.00 36.50 X 0 413551 42559 NANCY DALY MS MPH CEO & EXECUTIVE VP 36.50 1.00 X 0 415557 46187 0 1717833 110496 0 0 1 0 TRUE NORTH INC 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 DIRECT MAIL SOLICITATIONS 1193780 FAIRCOM NY 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 DIRECT MAIL SOLICITATIONS 653743 2 6418 95000 1806035 3566050 16273726 82417 21747229 GRANTS EXPERTISE 900009 312459 312459 312459 1980450 1980450 2356620 1719575 637045 637045 637045 0 1806035 35881 -35881 -35881 24641302 312459 0 2581614 17692699 17692699 385500 385500 1103000 1103000 5963492 1799875 1048700 3114917 34369 34369 60000 60000 35258 35258 1082357 239987 232111 610259 46138 46138 561540 29068 25763 506709 727824 3405 4566 719853 540312 188622 165597 186093 47149 26415 3849 16885 120732 37545 38268 44919 UBI TAX 5186 5186 28405556 21506116 1588481 5310959 12722183 5062629 5286368 5040333 246172 164928 89668691 99582379 107923414 109850269 173364 401810 5890831 4926484 2173918 3600008 1011216 1419496 9249329 10347798 X 42169176 47032655 56504909 52469816 98674085 99502471 107923414 109850269 -3764254 4592640 0 X X 0 1 X 1 0 X 29032906 31998377 27209762 34945083 22059688 145245816 29032906 31998377 27209762 34945083 22059688 145245816 19658904 125586912 908055 719934 2667684 1592952 1980450 7869075 269300 276883 546183 153661074 0.81730 0.67450 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 35692561 1997125 2783059 1394375 39078370 27740161 6504115 2786765 1338480 35692561 17571755 8235901 2772005 839500 27740161 17114411 2133374 -974377 711653 17561755 10363214 6170675 1125396 544874 17114411 1.00000 0 0 0 DUE TO ASCO 1419496 1419496 X 29234565 4592640 4592640 24641925 35258 -35881 -623 24641302 28406179 0 28406179 35258 -35881 -623 28405556 PART V, LINE 4: PERMANENTLY RESTRICTED NET ASSETS OF DONOR-RESTRICTED ENDOWMENT FUNDS ARE PRESERVED, ABSENT EXPLICIT DIRECTION FROM THE DONOR. INTEREST FROM THE PERMANENTLY RESTRICTED FUNDS IS INTENDED TO FUND FUTURE RESEARCH AND/OR EDUCATIONAL AWARDS. PART X, LINE 2: CONQUER CANCER IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("IRC"). IT HAS BEEN GRANTED PUBLIC CHARITY STATUS BY THE INTERNAL REVENUE SERVICE (THE "IRS") AND HAS BEEN CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. IN 2021, CONQUER CANCER GENERATED NO UNRELATED BUSINESS INCOME. IN 2020, CONQUER CANCER GENERATED UNRELATED BUSINESS INCOME FROM ADVERTISING SOLD IN CONJUNCTION WITH THE SOCIETY'S ANNUAL MEETING. UNRELATED BUSINESS INCOME TAX OF $0 AND $170,363 WAS RECOGNIZED IN THE FINANCIAL STATEMENTS, IN 2021 AND 2020 RESPECTIVELY. CONQUER CANCER ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). CONQUER CANCER BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, CONQUER CANCER IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2018. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -35,881. PART XII, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -35,881. PART V, LINES 1A-AG ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES AWARDS & GRANTS 313000 NORTH AMERICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 256000 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 202000 SOUTH ASIA 0 0 PROGRAM SERVICES AWARDS & GRANTS 141000 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 110000 SOUTH AMERICA 0 0 PROGRAM SERVICES AWARDS & GRANTS 70000 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES AWARDS & GRANTS 11000 0 0 0 0 0 0 1103000 0 1103000 EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR 50000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) CAREER PATHWAY 230000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CAREER DEVELOPMENT 200000 WIRE 0 NORTH AMERICA YOUNG INVESTIGATOR 50000 WIRE 0 NORTH AMERICA YOUNG INVESTIGATOR 100000 WIRE 0 NORTH AMERICA YOUNG INVESTIGATOR 50000 WIRE 0 NORTH AMERICA INNOVATION GRANT 20000 WIRE 0 NORTH AMERICA INNOVATION GRANT 20000 WIRE 0 SOUTH AMERICA YOUNG INVESTIGATOR 50000 WIRE 0 SOUTH AMERICA INNOVATION GRANT 20000 WIRE 0 SOUTH ASIA INNOVATION GRANT 20000 WIRE 0 SOUTH ASIA INNOVATION GRANT 20000 WIRE 0 SOUTH ASIA INNOVATION GRANT 20000 WIRE 0 SOUTH ASIA INNOVATION GRANT 20000 WIRE 0 SOUTH ASIA INNOVATION GRANT 60000 WIRE 0 SUB-SAHARAN AFRICA YOUNG INVESTIGATOR 50000 WIRE 0 SUB-SAHARAN AFRICA INNOVATION GRANTS 40000 WIRE 0 SUB-SAHARAN AFRICA INNOVATION GRANT 20000 WIRE 0 18 ANNUAL MEETING MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 26 27000 WIRE ANNUAL MEETING MERIT AWARD NORTH AMERICA 12 12000 WIRE ANNUAL MEETING MERIT AWARD EAST ASIA AND THE PACIFIC 11 11000 WIRE ANNUAL MEETING MERIT AWARD MIDDLE EAST AND NORTH AFRICA 2 2000 WIRE ANNUAL MEETING MERIT AWARD SOUTH ASIA 1 1000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 2 2000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 4 4000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 1 1000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1000 WIRE ASCO QUALITY CARE SYMPOSIUM MERIT AWARD NORTH AMERICA 1 1000 WIRE ASCO QUALITY CARE SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1000 WIRE 0 0 0 0 0 0 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL EARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. PART III ACCOUNTING METHOD: X X X X X X 1 FAIRCOM NEW YORK 12 WEST 27TH ST 13TH FLOOR NEW YORK NY 10001 ONLINE ADVERTISING 0 653743 60000 593743 653743 60000 593743 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI CONQUER CANCER DINNER- AM 1124242 1124242 4719 14372 WWC MAR SALON 103410 103410 3060 6 577004 577004 10870 1804656 1804656 4719 28302 33021 -33021 SCHEDULE G, PART I, LINE 2B, COLUMN (V) FAIRCOM NY- CONQUER CANCER PAYS A RETAINER FEE FOR FUNDRAISING SERVICES, INCLUDING STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. 1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 250000 0 CDA, GO YIA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DR STE 2200 CB 1350 CHAPEL HILL NC 275991350 566001393 GOVT ENTITY 850000 0 ACRA, CDA, YIA UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER 1200 CHILDRENS AVENUE OKLAHOMA CITY OK 73104 731563627 GOVT ENTITY 50000 0 YIA H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 30000 0 ASCO REGISTRY RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 830621846 501(C)(3) 50000 0 GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 100000 0 YIA UNIVERSITY OF COLORADO 13001 E 17TH PLACE ROOM W1124 AURORA CO 80045 846000555 GOVT ENTITY 102000 0 YIA, MEDICAL STUDENT ROTATION MENTORSHIP UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY CORAL GABLES FL 33146 590624458 501(C)(3) 200000 0 CDA CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 910103000 953432210 501(C)(3) 50000 0 YIA MD ANDERSON SERVICES CORPORATION 1515 HOLCOMBE BOULEVARD HOUSTON TX 770304009 760300816 501(C)(3) 300000 0 YIA EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 200000 0 CDA UNIVERSITY OF CALIFORNIA IRVINE 160 ALDRICH HALL IRVINE CA 926977600 952226406 GOVT ENTITY 50000 0 YIA UNIVERSITY OF CALIFORNIA DAVIS 1850 RESEARCH PARK DRIVE DAVIS CA 956186153 946036494 GOVT ENTITY 200000 0 CDA SEATTLE CHILDREN'S HOSPITAL 1900 NINTH AVENUE M/S 818-S SEATTLE WA 981011309 910564748 501(C)(3) 250000 0 CDA, YIA MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 500000 0 CDA, YIA UNIVERSITY OF WISCONSIN 21 N PARK ST SUITE 6401 MADISON WI 537151218 396006492 GOVT ENTITY 100000 0 YIA DUKE UNIVERSITY 2200 W MAIN ST STE 820 DURHAM NC 27705 560532129 501(C)(3) 452000 0 MSR, ACRA AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC 2318 MILL RD STE 800 ALEXANDRIA VA 22314 136180380 501(C)(3) 7797511 0 SUPPORT FOR: PROFESSIONAL DEVELOPMENT; EDUCATION, EQUITY, DIVERSITY & INCLUSION PROGRAMS; RESEARCH ON COVID-19 IMPACT ON ONCOLOGY PATIENTS YALE UNIVERSITY 25 SCIENCE PARK NEW HAVEN CT 06510 060646973 501(C)(3) 150000 0 YIA ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 250000 0 CDA, GO YIA THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA PA 19146 231352166 501(C)(3) 100000 0 YIA REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MO 48109 386006309 GOVT ENTITY 368400 0 CAREER PATHWAY GRANT IN SYMPTON MANAGEMENT OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97034 931176109 GOVT ENTITY 200000 0 CDA BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 200000 0 CDA VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE SUITE 970 NASHVILLE TN 37203 352528741 501(C)(3) 300000 0 CDA, YIA RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 191112434 236296135 501(C)(3) 100000 0 YIA UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94143 946036493 GOVT ENTITY 350000 0 CDA, YIA UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FL FRANKLIN BLDG PHILADELPHIA PA 191046205 231352685 GOVT ENTITY 100000 0 YIA RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 35 STATE STREET ALBANY NY 12207 141368361 501(C)(3) 50000 0 YIA UNIVERSITY OF SOUTH FLORIDA 4019 E FOWLER AVENUE SUITE 100 TAMPA FL 33617 593102112 GOVT ENTITY 50000 0 YIA UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 GOVT ENTITY 115000 0 CAREER PATHWAY GRANT IN SYMPTION MANAGEMENT DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 600000 0 CDA,YIA LELAND STANFORD JUNIOR UNIVERSITY 455 BROADWAY REDWOOD CITY CA 940633126 941156365 501(C)(3) 100000 0 YIA WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 455 MAIN STREET CAMBRIDGE MA 02142 061043412 501(C)(3) 50000 0 YIA UNIVERSITY OF CINCINNATI 51 GOODMAN DR SUITE 530 CINCINNATI OH 452210222 316000989 GOVT ENTITY 200000 0 CDA UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING - BOX 270140 ROCHESTER NY 14627 160743209 501(C)(3) 50000 0 YIA UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 GOVT ENTITY 50000 0 YIA UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 753909020 756002868 GOVT ENTITY 50000 0 YIA THE GENERAL HOSPITAL CORP DBA MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 041564655 501(C)(3) 480000 0 CAREER PATHWAY GRANT IN SYMPTON MANAGEMENT, YIA COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NJ 100327922 135598093 501(C)(3) 430000 0 ASCO REGISTRY RESEARCH GRANT, CDA, YIA JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB STE 117 BALTIMORE MD 212051832 520595110 501(C)(3) 400000 0 CDA BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02116 042312909 501(C)(3) 50000 0 YIA NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE CHICAGO IL 606114579 362167817 501(C)(3) 50000 0 YIA TUFTS MEDICAL CENTER 800 WASHINGTON STREET BOSTON MA 021111526 043400617 501(C)(3) 50000 0 YIA CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES CA 90048 951644600 501(C)(3) 200000 0 CDA CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 441950001 340714585 501(C)(3) 50000 0 YIA REGENTS OF THE UNIVERSITY OF UNIVERSITY OF CALIFORNIA AT SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 956006144 GOVT ENTITY 50000 0 YIA WASHINGTON UNIVERSITY IN ST LOUIS CAMPUS BOX 1054 ONE BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 100000 0 YIA BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 770303411 741613878 501(C)(3) 150000 0 YIA ASCO ASSOCIATION 2318 MILL RD STE 800 ALEXANDRIA VA 22314 833561693 501(C)(6) 6000 0 MEMBERSHIP ASSISTANCE 50 1 MERIT AWARDS 158 160000 MEDICAL STUDENT ROTATION AWARDS 26 215000 ANNUAL MEETING RESEARCH AWARDS 7 10500 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES AND SPONSORING INSTITUTIONS ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CONQUER CANCER AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT BY THE END OF THE PROJECT PERIOD OR TO MEET THE PROPOSED TIME SCHEDULES. CONQUER CANCER MAY APPROVE UP TO A MAXIMUM OF THREE NO-COST EXTENSIONS OF SIX MONTH INCREMENTS. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE THEIR SPONSORING INSTITUTION DURING THE COURSE OF THEIR GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (EXPENDITURE REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND AN EXPENDITURE REPORT ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF EACH GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, A FINAL PROGRESS REPORT AND A FINAL EXPENDITURE REPORT ARE REQUIRED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CONQUER CANCER. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROGRESS REPORT, FINAL EXPENDITURE REPORT, ANY REMAINING BALANCE ON THE GRANT, AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS OF THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. PART I, LINE 1 CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES AND SPONSORING INSTITUTIONS ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CONQUER CANCER AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT BY THE END OF THE PROJECT PERIOD OR TO MEET THE PROPOSED TIME SCHEDULES. CONQUER CANCER MAY APPROVE UP TO A MAXIMUM OF THREE NO-COST EXTENSIONS OF SIX MONTH INCREMENTS. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE THEIR SPONSORING INSTITUTION DURING THE COURSE OF THEIR GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (EXPENDITURE REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND AN EXPENDITURE REPORT ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF EACH GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, A FINAL PROGRESS REPORT AND A FINAL EXPENDITURE REPORT ARE REQUIRED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CONQUER CANCER. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROGRESS REPORT, FINAL EXPENDITURE REPORT, ANY REMAINING BALANCE ON THE GRANT, AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS OF THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. PART II, COLUMN H AWARD ABBREVIATIONS: YIA: YOUNG INVESTIGATOR AWARD GO YIA: GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD CDA: CAREER DEVELOPMENT AWARD MSR: MEDICAL STUDENT ROTATION AWARD ACRA: ADVANCED CLINICAL RESERACH AWARD 0 0 0 0 0 0 0 0 0 CLIFFORD HUDIS MD FACP FASCO CHIEF EXECUTIVE OFFICER 0 886337 0 1200 0 1188 0 21750 0 0 0 910475 0 0 NANCY DALY MS MPH CEO & EXECUTIVE VP 0 413369 0 1000 0 1188 0 21750 0 24437 0 461744 0 0 LINDA JENSEN CPA CFO & EXECUTIVE VP 0 410000 0 1200 0 2351 0 21750 0 20809 0 456110 0 0 PART I, LINE 3 COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. (ASCO). THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 8 82417 FMV 0 0 1 0 FORM 990, PART VI, SECTION A, LINE 1A AS OF DECEMBER 31, 2021, THE BOARD OF DIRECTORS OF CONQUER CANCER INCLUDED TWENTY (20) DIRECTORS WITH VOTING RIGHTS, AND TWO (2) WITHOUT VOTING RIGHTS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS HAVE THE SAME VOTING RIGHTS. DURING THE REPORTED TAX YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS CONSISTENT WITH CONQUER CANCER'S BYLAWS. THE EXECUTIVE COMMITTEE IS COMPOSED OF SIX MEMBERS, WHO ARE THE CHAIR OF THE BOARD OF DIRECTORS, THE SECRETARY, THE TREASURER, THE EXECUTIVE VICE CHAIR AND THE CHIEF EXECUTIVE OFFICER (NONVOTING), AND A SIXTH DIRECTOR WHO IS NOMINATED BY THE CHAIR OF THE BOARD AND ELECTED BY A MAJORITY OF THE VOTING MEMBERS OF THE BOARD OF DIRECTORS. ALL OF THE MEMBERS OF THE EXECUTIVE COMMITTEE EXCEPT THE CHIEF EXECUTIVE OFFICER ARE ENTITLED TO VOTE. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY CONQUER CANCER'S BYLAWS, WHICH PROVIDE THAT EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW AND EXCEPT AS SPECIFIED IN THE BYLAWS, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH CONQUER CANCER'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2 DR CLIFFORD HUDIS, NANCY DALY AND LINDA JENSEN ARE EMPLOYED BY ASCO. DR. HUDIS SERVED AS CHIEF EXECUTIVE OFFICER EO OF ASCO AND LINDA JENSEN SERVED AS CHIEF FINANCIAL OFFICER OF ASCO. DR. HOWARD BURRIS, III, SERVED AS CHAIR OF THE BOARD OF DIRECTORS AND PAST PRESIDENT OF ASCO. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE TAX RETURN, INCLUDING ALL APPLICABLE SCHEDULES, WAS PROVIDED TO THE BOARD OF DIRECTORS, CHIEF FINANCIAL OFFICERHI AND GENERAL COUNSEL FOR REVIEW AND COMMENT PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF EXECUTIVE OFFICER OF CONQUER CANCER, THE EXECUTIVE VICE CHAIR OF CONQUER CANCER, AND THE CHIEF FINANCIAL OFFICER OF CONQUER CANCER SERVE AS EMPLOYEES OF ASCO. INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION, INCLUDING REVIEW AND APPROVAL BY INDEPENDENT PERSONS, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION, ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. PART XII, LINE 2C THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 136180380 EDUCATION NY 501(C)(3) LINE 10 N/A 0 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561639 MEMBER SERVICES VA 501(C)(6) ASCO 0 ASCO ASSOCIATION PAC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 PAC VA 527 ASCO ASSOCIATION 0 0 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0